Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


MonumenTAL-1 Trial: Intensity of Dosing With Talquetamab in Myeloma Under Study

By: Joshua D. Madera, MD
Posted: Friday, January 5, 2024

Current investigative efforts have revealed the benefit of treatment with the T-cell–redirecting bispecific antibody talquetamab in patients with relapsed or refractory multiple myeloma. However, the impact of dose reduction on patients’ clinical outcomes remains elusive. Additional analyses performed on patients recruited for the MonumenTAL-1 study have demonstrated deepened or maintained responses to talquetamab after reduced-intensity dosing, according to a presentation given at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1010) by Ajai Chari, MD, of the Mount Sinai School of Medicine, New York, and colleagues. Patients typically experienced fewer treatment-related adverse events as a result of this modification, they explained.

“Further analyses on the impact of reduced or less-frequent talquetamab dosing on clinical outcomes are warranted,” suggested the investigators.

A total of 24 patients with relapsed or refractory multiple myeloma were included in the prospective cohorts in this study. Patients were randomly assigned to dose-reduction cohorts. Cohort A allowed patients who were initially treated with 0.8 mg/kg of talquetamab every 2 weeks to be reduced to 0.4 mg/kg every 2 weeks (n = 12). Cohort B allowed patients who were initially treated with 0.8 mg/kg of talquetamab every 2 weeks to receive treatment every 4 weeks (n = 12).

The study findings demonstrated achievement of at least a partial response to treatment in 9 patients from cohort A and 10 patients from cohort B. Of the 19 patients who demonstrated at least a partial response, 11 showed evidence of deepened responses, and 5 patients maintained the response after the change in dosing. Furthermore, treatment-related adverse events were observed and included oral-related (84.2%), nail-related (36.8%), and skin-related (42.1%) events.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.